Key Finding
There is no clear evidence for efficacy of acupuncture or herbal mixtures in treating infertility in women with PCOS, while clomiphene citrate and letrozole demonstrate effectiveness as first-line pharmacological ovulation induction therapies.
This comprehensive review examined treatments for women with polycystic ovary syndrome (PCOS) who have difficulty getting pregnant due to irregular or absent ovulation. PCOS affects approximately 80% of women with ovulation-related infertility. Researchers analyzed existing evidence to help the World Health Organization develop global treatment guidelines.
The study evaluated multiple treatment approaches including lifestyle changes, weight loss surgery, medications, and in-vitro fertilization (IVF). For obese women with PCOS, lifestyle modifications focusing on diet and exercise were recommended as the first step, primarily for overall health benefits. When lifestyle changes aren't sufficient, medications like clomiphene citrate or letrozole are recommended as first-line treatments to stimulate ovulation. Metformin alone showed limited benefit for improving pregnancy rates.
Regarding acupuncture, the researchers found no clear evidence supporting its effectiveness for treating infertility in women with PCOS. Similarly, herbal mixtures did not demonstrate proven benefits for improving fertility outcomes in this population. The analysis emphasized that carefully monitored medical treatments, including ovulation-inducing medications and IVF when needed, remain the evidence-based approaches for managing PCOS-related infertility.
The review stressed the importance of monitoring treatment closely to minimize risks such as multiple pregnancies and ovarian hyperstimulation syndrome. Women were also advised to understand pregnancy risks associated with PCOS, including how obesity can worsen outcomes for both mother and baby. If you're considering any complementary therapies for PCOS-related infertility, discuss them with your reproductive endocrinologist and seek care only from qualified, licensed practitioners.
This evidence synthesis supported WHO guideline development for anovulatory infertility management in PCOS, affecting approximately 80% of anovulatory infertility cases. The collaborative methodology involved systematic evidence retrieval, quality assessment (graded as very low to high), and stakeholder consensus across lifestyle interventions, pharmacotherapy, surgery, and IVF protocols. Recommendations prioritize lifestyle modification for obese patients, with clomiphene citrate or letrozole as first-line pharmacological ovulation induction. Metformin monotherapy demonstrated limited live birth rate improvements. Second-line options include gonadotropins and laparoscopic surgery. Critically, the analysis found no clear evidence supporting acupuncture or herbal mixture efficacy in PCOS fertility treatment. For IVF candidates, GnRH antagonist protocols are preferred; if agonist protocols are used, metformin may reduce ovarian hyperstimulation syndrome risk. Clinical emphasis includes minimizing multiple pregnancy rates through protocol adherence and counseling patients on treatment risks, pregnancy complications, and obesity's exacerbating impact on maternal-fetal outcomes. This represents global, evidence-based guidance for safe ovulation induction administration.
Browse our directory of verified licensed practitioners near you.
Find a practitioner →📌 Three distinct BNC1 gene variants contribute to premature ovarian insufficiency through different molecular mechanisms, with each variant affecting separate biological pathways including immune regulation, antiviral responses, and reproductive development.
📌 LbGP supplementation significantly improved oocyte quality in aged mice by restoring mitochondrial function through PPAR signaling activation and remodeling the ovarian microenvironment by reducing inflammation and increasing functional granulosa cells.
📌 Copper deficiency during pregnancy causes fetal growth restriction by disrupting placental structure, impairing trophoblast cell function, and dysregulating lipid metabolism in the placenta.